Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

<h4>Background</h4>The TLR9 agonist CpG is increasingly applied in preclinical and clinical studies as a therapeutic modality to enhance tumor immunity. The clinical application of CpG appears, however, less successful than would be predicted from animal studies. One reason might be the...

Full description

Bibliographic Details
Main Authors: Stefan Nierkens, Martijn H den Brok, Thijs Roelofsen, Jori A L Wagenaars, Carl G Figdor, Theo J Ruers, Gosse J Adema
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2009-12-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20020049/pdf/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20020049/pdf/?tool=EBI

Similar Items